beta
Trial Radar AI

Showing clinical trials matching location: Florida, United States.

I can help you find nearby clinical trials and understand health conditions and treatments.
51 Results
Top 50 Showing
 
Status (Default)
Not yet Recruiting, Recruiting, Active, Not Recruiting
×
 
Location
Florida, United States
×
 
Intervention
GLP-1
×
 
Study Title
Status
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring NCT06668935
Recruiting
RESCUE: Discontinuation of GLP-1 NCT07190794
Recruiting
The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality NCT07127354
Recruiting
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1) NCT06867718
Active, not recruiting
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) NCT07169136
Recruiting
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM (VESPER-2) NCT06897202
Active, not recruiting
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight (VESPER-1) NCT06712836
Active, not recruiting
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants NCT06737042
Not yet recruiting
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity (BMT-801) NCT06565611
Active, not recruiting
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia NCT07107334
Recruiting
Avexitide for Treatment of Post-Bariatric Hypoglycemia (LUCIDITY) NCT06747468
Active, not recruiting
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH NCT06410924
Active, not recruiting
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide (REMAIN-1) NCT06484114
Active, not recruiting
VK2735 for Weight Management Phase 3 (VANQUISH 1) NCT07104500
Active, not recruiting
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) NCT07104383
Recruiting
Acupressure Wristbands for GLP-1RA Related Nausea NCT06939517
Active, not recruiting
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese NCT06732245
Not yet recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy NCT07502508
Recruiting
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PLATEAU) NCT07446998
Recruiting
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients NCT06774079
Recruiting
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist (ARAY) NCT06851858
Active, not recruiting
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight (VESPER-3) NCT06973720
Active, not recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor NCT06221969
Active, not recruiting
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial NCT07505303
Not yet recruiting
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes NCT07284901
Recruiting
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes NCT07284979
Recruiting
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes NCT07284875
Recruiting
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects (GIO B) NCT03139305
Active, not recruiting
To Determine Tolerability to Glucagon Infusion in Obese Subjects (GIO) NCT02817659
Active, not recruiting
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB) NCT06651177
Recruiting
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight NCT06987513
Active, not recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) NCT07165028
Recruiting
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. (STARS extend) NCT05018286
Active, not recruiting
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity NCT07218445
Recruiting
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA) NCT06588296
Active, not recruiting
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) NCT06864026
Recruiting
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) NCT06857942
Recruiting
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT06603571
Active, not recruiting
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO) NCT06588283
Active, not recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight NCT06143956
Recruiting
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight NCT06643728
Active, not recruiting
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) NCT06662383
Active, not recruiting
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity (GYMINDA) NCT06965413
Active, not recruiting
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity NCT06037252
Active, not recruiting
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY) NCT05433584
Active, not recruiting
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both (REIMAGINE 5) NCT06534411
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO) NCT05556512
Active, not recruiting
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2) NCT06962280
Active, not recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC) NCT06937086
Recruiting
Liraglutide Effect in Atrial Fibrillation (LEAF) NCT03856632
Active, not recruiting